Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Ownership  |  Insiders

Stock Quote Today & Recent News Lexicon Pharmaceuticals Inc LXRX

Healthcare Biotechnology
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of... see more

Current News (NDAQ:LXRX)

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

GlobeNewswire 7 days ago

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

GlobeNewswire 10 days ago

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

GlobeNewswire 12 days ago

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans

GlobeNewswire November 4, 2025

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

GlobeNewswire October 30, 2025

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

GlobeNewswire October 14, 2025

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

GlobeNewswire October 8, 2025

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

GlobeNewswire September 22, 2025

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

GlobeNewswire September 17, 2025
View More News ››

Opinion & Analysis (NDAQ:LXRX)

Sanofi Pays Lexicon Pharma $260 Million to Settle Diabetes Drug Dispute

Streetwise Reports September 12, 2019
View More Opinion ››

Bullboard Posts (NDAQ:LXRX)

missed it by that much as

it was a bargain in the summer,another one on my watchlist,but you can't win them al,so glta.
coolfooldumbguy - January 2, 2020

Loss narrows and uptrend is born

LXRX moved above resistance and crossed its 50-day moving average.Next target SPlooks like $3Lexicon Pharmaceuticals Inc. reported fourth...
mart33 - March 24, 2008
View more Bullboard ››

AJN Resources Inc.

AJN Resources Inc.

AJN Resources Inc. is a Canada-based junior exploration company and is engaged in the exploration and evaluation of mineral ...
View More »